State Street Multi-Asset Real Return ETF (RLY)
Bank of America Corp DE Boosts Holdings in SPDR SSgA Multi-Asset Real Return ETF $RLY
Bank of America Corp DE raised its holdings in SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) by 7.1% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 888,051 shares of the company's stock after purchasing an additional 58,681 shares during
26,275 Shares in SPDR SSgA Multi-Asset Real Return ETF $RLY Acquired by Compound Planning Inc.
Compound Planning Inc. acquired a new position in shares of SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 26,275 shares of the company's stock, valued at approximately $950,000. Compound Planning
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) Short Interest Up 142.0% in February
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY - Get Free Report) was the target of a large growth in short interest in February. As of February 27th, there was short interest totaling 235,641 shares, a growth of 142.0% from the February 12th total of 97,374 shares. Approximately 1.1% of the company's shares are short sold.
RLY: Tactical ETF Focusing On Natural Resources And Infrastructure
The State Street SPDR SSGA Multi-Asset Real Return ETF targets real returns above inflation via active allocation across inflation-linked assets, real estate, commodities, and infrastructure. RLY's portfolio is currently heavily weighted in equities related to natural resources and infrastructure, offering strong value characteristics. RLY has reached its objective to outperform inflation in total return since 2012 but has lagged 60/40 and permanent portfolios.
Catalyst Financial Partners LLC Has $1.68 Million Stake in SPDR SSgA Multi-Asset Real Return ETF $RLY
Catalyst Financial Partners LLC lifted its position in shares of SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) by 43.6% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 54,303 shares of the company's stock after buying an
Thrivent Financial for Lutherans Grows Holdings in SPDR SSgA Multi-Asset Real Return ETF $RLY
Thrivent Financial for Lutherans lifted its position in shares of SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) by 81.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 134,661 shares of the company's stock after buying an
Thrivent Financial for Lutherans Has $2.16 Million Stake in SPDR SSgA Multi-Asset Real Return ETF $RLY
Thrivent Financial for Lutherans grew its stake in shares of SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) by 145.2% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 74,308 shares of the company's stock after purchasing an additional 44,003 shares during the period. Thrivent
SPDR SSgA Multi-Asset Real Return ETF $RLY is First International Bank & Trust’s 3rd Largest Position
First International Bank and Trust cut its stake in shares of SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) by 3.5% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 776,930 shares of the company's stock after selling 28,069 shares during the period. SPDR SSgA
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongoing CAMBRIDGE, Mass., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced a subset analysis of interim clinical data for zovegalisib (RLY-2608), the first known investigational allosteric, pan-mutant and isoform-selective inhibitor of PI3Kα.
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY) Reaches New 52-Week High – Should You Buy?
SPDR SSgA Multi-Asset Real Return ETF (NYSEARCA:RLY - Get Free Report) hit a new 52-week high during trading on Friday. The company traded as high as $31.76 and last traded at $31.7240, with a volume of 4621 shares trading hands. The stock had previously closed at $31.56. SPDR SSgA Multi-Asset Real Return ETF Trading
Relay Therapeutics Is A Buy For Its Superb Safety Data
Relay Therapeutics leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety and efficacy in advanced breast cancer. RLY-2608's phase 1/2 trial data demonstrates higher response rates and significantly lower toxicity compared to existing therapies like alpelisib and inavolisib. The Eli Lilly acquisition of STX-478 from Scorpion Therapeutics highlights the value of allosteric PI3Kα inhibitors, positioning RLAY as undervalued and ahead in clinical development.
Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer
Relay Therapeutics: A Precision Oncology Play Worth The Risk
Relay Therapeutics focuses on selective small-molecule inhibitors, with RLY-2608 showing promise in breast cancer and a solid cash position lasting into 2027. Financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns about expense control and sustainable cash flow. Out-licensing RLY-4008 to Elevar Therapeutics secures up to $500 million in milestones, allowing RLAY to concentrate on RLY-2608's clinical trials.
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
New interim data show 11.4-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
Company to host conference call on Wednesday, December 11, 2024 at 7am ET Company to host conference call on Wednesday, December 11, 2024 at 7am ET
Relay Therapeutics: 2nd-Line RLY-2608 Data Moves Program Towards Expansion
Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + fulvestrant for treatment of PI3Ka-mutated HR+/HER2- locally advanced or metastatic breast cancer patients. Key upcoming milestones for RLY-2608 program includes presenting data at the San Antonio Breast Cancer Symposium in December 2024 and initiating a phase 3 study in 2025. Expansion opportunities of the RLY-2608 program includes two triplet regimens targeting 1st-line PI3Ka-mutant HR+/HER2- breast cancer patients and phase 1 study for tumors with vascular formations starting in Q1 2025.
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα Mutations
Relay Therapeutics' Dynamo platform combines machine learning and physics-based simulation to target dynamic protein conformations for oncology and genetic disease therapies. RLY-2608 targets PI3Kα-mutated HR+/HER2- breast cancer, with promising Phase 2 results and potential approval by 2026-2027. The company's RLY-4008 targets FGFR2-altered cholangiocarcinoma, and it is seeking pivotal trials and a commercialization partner to unlock broader market potential.
Relay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival
9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D 33% ORR across all patients & 53% ORR in patients with kinase mutations at RP2D Favorable overall tolerability profile; at RP2D, only 2 patients discontinued treatment due to adverse events & only 1 patient experienced Grade 3 hyperglycemia Data support planned initiation of 2L pivotal study in 2025 Triplet combination with ribociclib expected to move into dose expansion in 1H 2025 & triplet combination with atirmociclib (CDK4) remains on track to start before year-end Relay Therapeutics to host a conference call today, September 9, at 8:00 a.m. ET CAMBRIDGE, Mass.
Relay Therapeutics Announces Webcast to Report RLY-2608 Data on September 9, 2024
Interim data to be reported for RLY-2608 600mg BID + fulvestrant in 2L+, CDK4/6-experienced patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Conference call to be held Monday, September 9, at 8am ET CAMBRIDGE, Mass., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced plans to host a conference call and webcast to report data for RLY-2608 600mg BID + fulvestrant in the ongoing ReDiscover trial in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer and next steps on Monday, September 9, 2024, at 8:00 a.m.
RLY: A Nice Allocation Fund
Asset allocation is still important despite recent performance trends. SPDR® SSgA Multi-Asset Real Return ETF offers a mix of asset class exposure for real returns. The RLY ETF focuses on inflation-protected securities, real estate securities, commodities, and infrastructure companies.